Nanjing Sanhome Pharmaceutical Co., Ltd, a Chinese pharmaceutical company, and China Resource Pharmaceutical Commercial Group have been engaged in extensive business discussions across various locations in China, including Tianjin, Chengdu, Hebei, Shanghai, and Shanxi, with the strategic goal of expanding their market presence.
The collaboration between the two entities focuses on several key areas, including joint efforts on variety development, online sales of pharmaceutical products, and continuous monitoring of volume-based procurement (VBP) varieties. They have established a tier-one delivery partnership, which is expected to enhance the distribution channels for their products. Discussions have also revolved around oritinib, a Category 1 chemical developed by Sanhome Pharma that received marketing approval in China in June. The companies have explored market coverage and access strategies for Sanhome Pharma’s brand products, as well as its portfolio of originator new products and investigational pipelines. Furthermore, they have delved into exploring cooperation models for launching new products in the market.- Flcube.com
